bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
NTBNP

Order Name:
Pro-BNP (NT pro B-Natriuretic peptide)

 
Useful For:
  • Determination of N‑terminal pro B‑type natriuretic peptide in human plasma.
  • Indicated as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction.
  • Aids in the assessment of heart failure severity in patients diagnosed with congestive heart failure.
  • Indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure.

Used for monitoring the treatment in patients with left ventricular dysfunction.
 
Methodology:
Electrochemiluminescence method (ECLIA)
 
AliasesName:
NT Pro BNP
NT pro B-Natriuretic peptide
N Terminal proBNP
ProBNP (B-Type Natriuretic Peptide)
 
 
 
Test Code:
NTBNP

Order Name:
Pro-BNP (NT pro B-Natriuretic peptide)

 
Collection Specimen Or Container:
Blood/ Lithium heparin (Green top) 6 mL, 1 tube
 
Specimen Testing Type:
Lithium heparin Plasma, minimum volume 1 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: 4+ reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Lithium heparin plasma (keep in original tube) Room temperature, 20oC to 28oC 2 hours
Lithium heparin plasma Room temperature, 20oC to 28oC 3 days
Refrigerated, 2oC to 8oC 6 days
Frozen, -20oC 24 months
 
 
 
Test Code:
NTBNP

Order Name:
Pro-BNP (NT pro B-Natriuretic peptide)

 
Method detail:
Electrochemiluminescence method (ECLIA)
 
Schedule:
Tested Daily (24 Hours)
 
Turnaround Time:
Specimen collected to reported within 50 Mins.
 
Performing Location:
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
NTBNP

Order Name:
Pro-BNP (NT pro B-Natriuretic peptide)

 
 
Clinical Information:
The test is also useful in the early stages of heart failure, where symptoms may be transient rather than present all the time. The high sensitivity of NT‑proBNP allows also the detection of mild forms of cardiac dysfunction in asymptomatic patients with structural heart disease. NT‑proBNP can also be used for prognostic applications in patients with acute coronary syndrome. The GUSTO IV study, with more than 6800 patients, showed that NT‑proBNP was the strongest independent predictor of one year mortality in patients with acute coronary syndrome. In chronic heart failure, serial measurement of NT‑proBNP concentration can be used to monitor the disease progression, to predict outcomes and evaluate the success of treatment. Elevated NT‑proBNP values are strongly predictive of adverse outcomes and rising values identify a risk, while significant lowering of NT‑proBNP denotes improved outcomes and better prognosis. In addition NT‑proBNP can be used to identify patients at higher risk of cardiotoxicity which can lead to heart failure and may be helpful in
monitoring the use and dosing of cardiotoxic tumor drugs or interventions causing fluid retention or volume overload (e.g. COX‑2 inhibitors, nonsteroidal anti‑inflammatory drugs).
 
Reference Value:
Diagnosis
Rule-in acute heart failure (HFSA)
Heart failure can be ruled-in in the emergency department by using age-stratified cut points.
.
Patient age (years) NT-proBNP values (pg/mL)
< 50 < 300 300 - 450  > 450
50 - 75 < 300 300 - 900 > 900
> 75 < 300 300 - 1,800 > 1,800
Interpretation

 
Acute HF unlikely

 
Acute HF less likely,
alternative causes
must be considered
Acute HF likely,
consider contounding
factors
NT-proBNP levels are affected by several factors other than acute CHF and those should therefore be incorporated into clinical decision making.  For example, NT-proBNP can be elevated in patients with acuye coronary syndrome (ACS), pulmonary embolism, shock, atrial arrhythmias, severe pneumonia, renal insufficiency or prior CHF

Reference:
Januzzi JL et al. Eur heart J 2006; 27:330-337; Heart Failure Society of America. J Card Fail 2006; 12:e1-2.
 
Clinical Reference:
  1. Manufacturer’s Reagent package insert, Elecsys and cobas e analyzers ProBNP, 2018-12, V.13, Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim.                  
  2. Reference range: Januzzi JL et al. Eur Heart J 2006; 27:330-337; Heart Failure Society of America. J Card Fail 2006; 12:e1-2.